TY - JOUR
T1 - Human blood-brain barrier insulin-like growth factor receptor
AU - Duffy, Kent R.
AU - Pardridge, William M.
AU - Rosenfeld, Ron G.
N1 - Funding Information:
From the Departments of Medicine/Endocrinology and Surgery/ Neurosurgery, UCLA School of Medicine, Los Angeles: and the Department of Pediatrics, Stanford University School of Medicine. Stanford, CA. Supported by the Juvenile Diabeles Foundation, NIH grants ROI-AM28229 and RCDA AM-01275, and the US Army Medical Research and Development Command under Contract No. DAMD17-87-C-7137. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the US Army. Presented at the Western Section American Federation of Clinical Research, Carmel, CA in February 1987 and at the American Society of Clinical Investigation, San Diego in May 1987. Address reprint requests to William M. Pardridge, MD, Department of Medicine, Division of Endocrinology, UCLA School of Medicine, Los Angeles, CA 90024. 0 1988 by Grune & Stratton, Inc. 0026/0495/88/3702-0007$03.00/O
PY - 1988/2
Y1 - 1988/2
N2 - Insulin-like growth factor(IGF)-1 and IGF-2, may be important regulatory molecules in the CNS. Possible origins of IGFs in brain include either de novo synthesis or transport of circulating IGFs from blood into brain via receptor mediated transcytosis mechanisms at the brain capillary endothelial wall, ie, the blood-brain barrier (BBB). In the present studies, isolated human brain capillaries are used as an in vitro model system of the human BBB and the characteristics of IGF-1 or IGF-2 binding to this preparation were assessed. The total binding of IGF-2 at 37°C exceeded 130% per mg protein and was threefold greater than the total binding for IGF-1. However, at 37°C nonsaturable binding equaled total binding, suggesting that endocytosis is rate limiting at physiologic temperatures. Binding studies performed at 4°C slowed endocytosis to a greater extent than membrane binding, and specific binding of either IGF-1 or IGF-2 was detectable. Scatchard plots for either peptide were linear and the molar dissociation constant of IGF-1 and IGF-2 binding was 2.1 ± 0.4 and 1.1. ± 0.1 nmol/L, respectively. Superphysiologic concentrations of porcine insulin inhibited the binding of both IGF-1 (ED50 = 2 μg/mL) and IGF-2 (ED50 = 0.5 μg/mL). Affinity cross linking of 125I-IGF-1, 125I-IGF-2, and 125I-insulin to isolated human brain capillaries was performed using disuccinimidylsuberate (DSS). These studies revealed a 141 kd binding site for both IGF-1 and IGF-2, and a 133 kd binding site for insulin. No high molecular weight binding site for IGF-2 was detected. In conclusion, these studies suggest that a type 1 IGF receptor is present on isolated human brain capillaries that binds both IGFs, with a slightly higher affinity for IGF-2. The threefold greater activity of this receptor for IGF-2 relative to IFG-1 parallels the much higher concentration of IGF-2 in human brain and CSF (relative to IGF-1). These results are consistent with the hypothesis that the human BBB IGF receptor is a transport system for the circulating peptides, particularly for IGF-2.
AB - Insulin-like growth factor(IGF)-1 and IGF-2, may be important regulatory molecules in the CNS. Possible origins of IGFs in brain include either de novo synthesis or transport of circulating IGFs from blood into brain via receptor mediated transcytosis mechanisms at the brain capillary endothelial wall, ie, the blood-brain barrier (BBB). In the present studies, isolated human brain capillaries are used as an in vitro model system of the human BBB and the characteristics of IGF-1 or IGF-2 binding to this preparation were assessed. The total binding of IGF-2 at 37°C exceeded 130% per mg protein and was threefold greater than the total binding for IGF-1. However, at 37°C nonsaturable binding equaled total binding, suggesting that endocytosis is rate limiting at physiologic temperatures. Binding studies performed at 4°C slowed endocytosis to a greater extent than membrane binding, and specific binding of either IGF-1 or IGF-2 was detectable. Scatchard plots for either peptide were linear and the molar dissociation constant of IGF-1 and IGF-2 binding was 2.1 ± 0.4 and 1.1. ± 0.1 nmol/L, respectively. Superphysiologic concentrations of porcine insulin inhibited the binding of both IGF-1 (ED50 = 2 μg/mL) and IGF-2 (ED50 = 0.5 μg/mL). Affinity cross linking of 125I-IGF-1, 125I-IGF-2, and 125I-insulin to isolated human brain capillaries was performed using disuccinimidylsuberate (DSS). These studies revealed a 141 kd binding site for both IGF-1 and IGF-2, and a 133 kd binding site for insulin. No high molecular weight binding site for IGF-2 was detected. In conclusion, these studies suggest that a type 1 IGF receptor is present on isolated human brain capillaries that binds both IGFs, with a slightly higher affinity for IGF-2. The threefold greater activity of this receptor for IGF-2 relative to IFG-1 parallels the much higher concentration of IGF-2 in human brain and CSF (relative to IGF-1). These results are consistent with the hypothesis that the human BBB IGF receptor is a transport system for the circulating peptides, particularly for IGF-2.
UR - http://www.scopus.com/inward/record.url?scp=0023830889&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023830889&partnerID=8YFLogxK
U2 - 10.1016/S0026-0495(98)90007-5
DO - 10.1016/S0026-0495(98)90007-5
M3 - Article
C2 - 2963191
AN - SCOPUS:0023830889
SN - 0026-0495
VL - 37
SP - 136
EP - 140
JO - Metabolism
JF - Metabolism
IS - 2
ER -